From Skeptic to Advocate: Wes Ely, Long COVID and his Baricitinib Trial
- Condition
- Long COVID
- At worst
- Not stated
- Ill for
- Not stated
- Published
- Jan 2024
Summary
Nik took baricitinib for a few months as part of long-COVID treatment; the page does not say how long or how severely Nik had been ill beforehand. The drug worked well, reducing both post-exertional malaise and brain fog. Nik had to stop taking it, though, because of recurrent infections caused by its immunosuppressive effect, so the benefit ended when treatment was discontinued rather than fading on its own.
What they credit
Credits Biologics & antibodies, JAK inhibitors (Rinvoq, baricitinib).
Similar stories
-
Monoclonal antibodies article comments (Chris)
Chris is participating in a Vanderbilt clinical trial of baricitinib for long COVID, having started the drug on October 18, 2025. He reported feeling "the best I have since I got Covid," becoming functional though still limited. As of his comment he was…
-
Filgotinib (JAK1 inhibitor) - future of CFS/ME treatment
Took filgotinib 200mg for three days in early 2023, after about three years of suspected ME/CFS that at its worst left him housebound, able to walk ten minutes before needing hours of rest and to sit upright only twenty minutes at a stretch while working…
-
Three clinical trials for Long COVID are testing JAK inhibitors (unnamed)
Credits upadacitinib. An unnamed patient had long COVID and reports a substantial improvement. Other two on the same drug worsened over six weeks.
-
Three clinical trials for Long COVID are testing JAK inhibitors (Jen)
Jen took the JAK inhibitor upadacitinib (Rinvoq) for 66 days starting December 2023 before stopping early due to profound weakness and paralyzing fatigue with no apparent benefit while on the drug. She had suffered from severe myalgic encephalomyelitis for…